US69353Y1038

PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

October 24, 2025 11:39 ET | Source: PMV Pharmaceuticals, Inc. Data presented today as an oral presentation at 2025 AACR-NCI-EORTC…

1 month ago